



Under the High Patronage of  
**His Majesty Mohammed VI, King of Morocco**

**M** **MSDA** 2010  
**7<sup>th</sup> Metabolic Syndrome, type II Diabetes  
and Atherosclerosis congress**

MARRAKESH  
MAY 12<sup>th</sup> - 16<sup>th</sup>  
2010

P R O G R A M

The Scientific Committee and the Organizing Secretariat thank warmly the following actors for their support and contribution to the 7<sup>th</sup> Metabolic Syndrome, type II Diabetes and Atherosclerosis congress.

## Under the aegis of



INTERNATIONAL  
ATHEROSCLEROSIS  
SOCIETY



EAS  
EUROPEAN ATHEROSCLEROSIS SOCIETY



International Task Force  
for Prevention of  
Coronary Heart Disease



Fondation  
Cœur et Artères  
Recherche et Prévention  
Nutrition et Santé



## Gold sponsor

Solvay  
Pharmaceuticals



Solvay Pharmaceuticals is now Abbott

## Silver sponsor



## With the support of



## Welcome address

Dear Colleagues,

On behalf of the Organizing Committee, I am very glad to welcome you to the 7<sup>th</sup> edition of the « Metabolic Syndrome, type II Diabetes and Atherosclerosis » congress to be held in Marrakesh (Morocco) from May 12<sup>th</sup> to May 16<sup>th</sup>, 2010.

Since its creation, this meeting welcomes a wide number of participants, from all over the world, involved in the atherosclerosis and cardiovascular diseases fields. It covers every item from evolution to definition, from basic research to the latest therapeutic managements and prevention.

Benefiting since its creation from the support of many scientific societies especially the “International Atherosclerosis Society”, the “European Atherosclerosis Society”, the “International Task Force for prevention of Coronary Heart Disease”, the “Fondation Cœur et Artères”, the “Nouvelle Société Française d’Athérosclérose” and the “ Société Française d’Endocrinologie”, the Congress has been designed to provide an innovative and comprehensive overview of the latest research developments in Metabolic Syndrome, Diabetes and Atherosclerosis.

Experts from different fields (cardiologists, diabetologists and scientists) have been invited and will present and discuss a full spectrum of pertinent topics relating to these items in the form of plenary sessions and symposia.

And finally, the Congress offers the occasion to the participants to present their own papers, so giving the opportunity to share knowledge.

I hope that you will enjoy the Congress and that your interaction with your colleagues from many different countries will stimulate a creative exchange of ideas.

Yours sincerely,

Professor Jean-Charles Fruchart  
President of the International Atherosclerosis Society  
Chairman

### SCIENTIFIC AND ORGANIZING COMMITTEE


#### Chair:

Pr Jean-Charles FRUCHART (France)  
President of the International  
Atherosclerosis Society

#### Members:

Dr Jamila FRUCHART-NAJIB  
Pr Patrick DURIEZ  
Pr Michel HERMANS

## Exhibition map



## C O N T E N T S

Welcome address .....	3
Scientific and organizing committee .....	3
Exhibition map .....	4
Program at a glance .....	7
<b>DETAILED PROGRAM</b>	
Wednesday May 12, 2010 .....	8
Thursday May 13, 2010	
morning .....	8
afternoon .....	9
Friday May 14, 2010	
morning .....	10
afternoon .....	12
Saturday May 15, 2010	
morning .....	14
afternoon .....	15
<b>LIST OF ABSTRACTS</b> .....	16
Information to the faculty and poster authors .....	24
General information .....	26
The congress from A to Z .....	28



## Program at a glance

WEDNESDAY MAY 12 <sup>th</sup>	THURSDAY MAY 13 <sup>th</sup>	FRIDAY MAY 14 <sup>th</sup>	SATURDAY MAY 15 <sup>th</sup>
	<p><b>08:30 am / 10:00 am</b>  <b>ACADEMIC SESSION I</b>                      Metabolic disorders: global risks, diagnosis and management  <i>Chair: Brewer B. (USA)</i>                      Odawara M. (Japan)                      Amarenco P. (France)                      Ogawa H. (Japan)</p>	<p><b>08:30 am / 10:30 am</b>  <b>R<sup>3</sup> SYMPOSIUM</b>                      Lipid-related residual vascular risk. Opening the new era of vascular prevention  <i>Fruchart J.-C. (France)</i>                      Sacks F. (USA)                      Hermans M. (Belgium)                      Ginsberg H. (USA)</p>	<p><b>09:00 am / 10:30 am</b>  <b>ACADEMIC SESSION V</b>                      Metabolic and genetic biomarkers  <i>Chair: Carmena R. (Spain)</i>                      Davignon J. (Canada)                      Koenig W. (Germany)                      Froguel P. (France)</p>
	<p><b>10:00 am / 10:45 am</b>                      State of the Art Lecture  <i>Chair: Fruchart J.-C. (France)</i>                      Al-Rubeaan K. (Saudi Arabia)</p>		
	<p><b>10:45 / 11:15 am</b>                      COFFEE BREAK</p>	<p><b>10:30 am / 11:00 am</b>                      COFFEE BREAK</p>	<p><b>10:30 am / 11:00 am</b>                      COFFEE BREAK</p>
	<p><b>11:15 am / 12:45 pm</b>                      SYMPOSIUM SPONSORED BY  <b>SOLVAY PHARMACEUTICALS NOW ABBOTT</b>                      The unfinished business in vascular risk reduction  <i>Chair: Fruchart J.-C. (France)</i>                      Fruchart J.-C. (France)                      Elam M. (USA)                      O'Brien R. (Australia)                      Bersot T. (USA)</p>	<p><b>11:00 am / 12:30 pm</b>                      SYMPOSIUM SPONSORED BY KOWA                      Future therapeutic approaches for atherosclerosis                      Potential and application of novel statin  <i>Chair: Kita T. (Japan)</i>                      Matsuzawa Y. (Japan)                      Corsini A. (Italy)                      Egashira K. (Japan)</p>	<p><b>11:00 am / 12:30 pm</b>  <b>ACADEMIC SESSION VI</b>                      No traditional risk factors of cardiometabolic disease  <i>Chair: Sadikot S.M. (India)</i>                      Ahmed Q. (USA)                      Guzik T. (Poland)                      Rouis M. (France)</p>
	<p><b>12:45 pm / 02:00 pm</b>                      LUNCH</p>	<p><b>12:30 pm / 02:00 pm</b>                      LUNCH</p>	<p><b>12:30 pm / 02:00 pm</b>                      LUNCH</p>
	<p><b>02:00 pm / 03:30 pm</b>  <b>FONDATION CŒUR ET ARTÈRES SYMPOSIUM</b>                      Statins and fibrates in CHD prevention: where are we now ?  <i>Chair: Creten H. (Germany)</i>                      Assmann G. (Germany)                      Packard C. (UK)                      Zamboni A. (Italy)                      Valensi P. (France)</p>	<p><b>02:00 pm / 03:30 pm</b>  <b>ACADEMIC SESSION III</b>                      Lifestyle and exercise versus medical therapies in prevention and management of the metabolic syndrome  <i>Chair: Sacks F. (USA)</i>                      Farinaro E. (Italy)                      Kodama T. (Japan)                      Carmena R. (Spain)</p>	<p><b>02:00 pm / 03:00 pm</b>                      ORAL COMMUNICATIONS SELECTED FROM ABSTRACTS  <i>Chair: Rouis M. (France)</i></p>
<p><b>05:30 pm</b>                      CONGRESS OPENING CEREMONY</p>	<p><b>03:30 pm / 04:00 pm</b>                      COFFEE BREAK</p>	<p><b>03:30 pm / 04:00 pm</b>                      COFFEE BREAK</p>	<p><b>03:00 pm / 03:30 pm</b>                      COFFEE BREAK</p>
<p><b>06:00 pm</b>                      OPENING LECTURE  <i>Chair: Fruchart J.-C. (France)</i>                      Metabolic syndrome ? From new epidemiology to new definition: who is the violin in the quartet ?                      Shlyakhto E. (Russia)</p>	<p><b>04:00 pm / 05:30 pm</b>  <b>ACADEMIC SESSION II</b>                      New targets in drug development  <i>Chair: Hermans M. (Belgium)</i>                      Krempf M. (France)                      Gupta S. (UK)                      Duriez P. (France)</p>	<p><b>04:00 pm / 05:30 pm</b>  <b>ACADEMIC SESSION IV</b>                      Metabolic dyslipoproteinemia and atherosclerosis  <i>Chair: Davignon J. (Canada)</i>                      Sadikot S. M. (India)                      Ceska R. (Czech Republic)                      Brewer B. (USA)</p>	<p><b>03:30 am / 05:30 am</b>  <b>POSTER SESSION</b>  <i>Chair: Fruchart J.-C. (France)</i>                        END OF THE CONGRESS</p>

## Wednesday May 12<sup>th</sup>, 2010

SALLE DES MINISTRES

05:30 pm ■ Opening Ceremony

06:00 pm ■ Opening Lecture

Chair: Fruchart Jean-Charles (France)

- Metabolic syndrome ? From new epidemiology to new definition: who is the violin in the quartet ?
- Shlyakhto Evgeny (Russia)

## Thursday May 13<sup>th</sup>, 2010 / Morning

SALLE DES MINISTRES

08:30 am ■ **ACADEMIC SESSION I**

10:00 am ■ **Metabolic disorders: global risks, diagnosis and management**

Chair: Brewer Bryan (USA)

- Aggressive intervention for dyslipidemia with the aim of controlling complications in Japanese diabetic patients ..... Odawara Masato (Japan) **AL-01**
- An update of glucose and lipid management in the prevention of stroke ..... Amarenco Pierre (France) **AL-02**
- Low-dose Aspirin for primary prevention of atherosclerotic events in patients with type II diabetes ..... Ogawa Hisao (Japan) **AL-03**

10:00 am ■ **State of the Art Lecture**

10:45 am ■ Chair: Fruchart Jean-Charles (France)

- Metabolic syndrome in the Middle East: a real challenge ..... Al-Rubeaan Khalid (Saudi Arabia) **AL-04**

10:45 am ■ **Coffee Break**

11:15 am

12:45 pm ■ **SYMPOSIUM SPONSORED BY SOLVAY PHARMACEUTICALS NOW ABBOTT**

**The unfinished business in vascular risk reduction**

Chair: Fruchart Jean-Charles (France)

- Defining and addressing the residual vascular risk; the atherogenic dyslipidemia factor ..... Fruchart Jean-Charles (France) **LL-01**
- How ACCORD will impact the way we treat patients with T2D ? ..... Elam Marshall (USA) **LL-02**
- FIELD: anything new ? ..... O'Brien Richard (Australia) **LL-03**
- Fibrates & statins: combination therapy, the way forward ..... Bersot Thomas (USA) **LL-04**



Thursday May 13<sup>th</sup>, 2010 / Afternoon

SALLE DES MINISTRES

12:45 pm  
02:00 pm

Lunch

02:00 pm  
03:30 pm

**FONDATION CŒUR ET ARTÈRES SYMPOSIUM**

Statins and fibrates in CHD prevention: where are we now ?

Chair: Greten Heiner (Germany)

- First debate: should we give the statins in primary prevention to all people ? ..... Assmann Gerd (Germany) / Packard Chris (UK) **LL-05**
- Second debate: should we give the fibrates to all diabetic patients ? ..... Zambon Alberto (Italy) / Valensi Paul (France) **LL-06**

03:30 pm  
04:00 pm

Coffee Break

04:00 pm  
05:30 pm

**ACADEMIC SESSION II**

New targets in drug development

Chair: Hermans Michel (Belgium)

- PSCK9: a translational research story ..... Krempf Michel (France) **AL-05**
- Ethnicity and CVD... and what role for the PolyPill in 2010 ? ..... Gupta Sandeep (UK) **AL-06**
- PPAR  $\alpha$  agonist and stroke ..... Duriez Patrick (France) **AL-07**

Friday May 14<sup>th</sup>, 2010 / Morning

SALLE DES MINISTRES

08:30 am  
10:30 am

**R<sup>3</sup>i SYMPOSIUM**

Lipid-related residual vascular risk.  
Opening the new era of vascular prevention

**Introduction**

- Fighting the residual vascular risk: time has come to act ! ..... Fruchart Jean-Charles (France) **LL-07**

**The R<sup>3</sup>i REALIST studies: a worldwide epidemiological approach to lipid-related residual risk**

- Exploring the association between atherogenic dyslipidemia and macrovascular residual risk: results from pilot centers ..... Sacks Frank (USA) **LL-08**
- Exploring the association between atherogenic dyslipidemia and microvascular residual risk: results from pilot centers ..... Hermans Michel (Belgium) **LL-09**

**Reducing the residual vascular risk: lessons from recent studies**

- ARBITER 6 - HALTS: settings the stage for an effective residual macrovascular risk management strategy ..... Sacks Frank (USA) **LL-10**
- ACCORD: a pharmacological approach to macrovascular and microvascular risk reduction in patients with diabetes ..... Ginsberg Henry (USA) **LL-11**

**Discussion and wrap-up**

10:30 am  
11:00 am

**Coffee Break**

## Join the R<sup>3</sup>i Community

Help us improve and extend the life of patients

- 
- Worldwide academic, non-profit, educational initiative
  - Present in over 40 countries with almost 200 experts
  - Committed to reducing the burden of residual vascular risk that patients still face despite current standards of care
- 

Join us today on  
[www.r3i.org](http://www.r3i.org)

Friday May 14<sup>th</sup>, 2010 / Afternoon

SALLE DES MINISTRES

11:00 am  
12:30 pm

**SYMPOSIUM SPONSORED BY KOWA**

**Future therapeutic approaches for atherosclerosis  
Potential and application of novel statin**

Chair: Kita Toru (Japan)

- From the dawn of the statin era to the present day ..... Matsuzawa Yuji (Japan) **LL-12**
- What are we looking for in a statin today and what are the  
future steps? ..... Corsini Alberto (Italy) **LL-13**
- Impact of nanotechnology-based selective delivery of pitavastatin for the development  
of innovative treatment of ischemic cardiovascular diseases ..... Egashira Kensuke (Japan) **LL-14**

12:30 pm  
02:00 pm

Lunch

02:00 pm  
03:30 pm

**ACADEMIC SESSION III**

**Lifestyle and exercise versus medical therapies in prevention and management  
of the metabolic syndrome**

Chair: Sacks Frank (USA)

- Lifestyle and CHD prevention with particular focus on nutrition.  
Yesterday, today and tomorrow ..... Farinaro Eduardo (Italy) **AL-08**
- Epigenomics and metabolic syndrome ..... Kodama Tatsuhiko (Japan) **AL-09**
- New approaches in the treatment of diabetic dyslipidemia ..... Carmena Rafael (Spain) **AL-10**

03:30 pm  
04:00 pm

Coffee Break

04:00 pm  
05:30 pm

**ACADEMIC SESSION IV**

**Metabolic dyslipoproteinemia and atherosclerosis**

Chair: Davignon Jean (Canada)

- Managing dyslipidemia in developing countries:  
problems and possibilities ..... Sadikot Shaikat M. (India) **AL-11**
- What is the priority in cardiometabolic risk treatment? ..... Ceska Richard (Czech Republic) **AL-12**
- HDL infusions in the treatment of the high risk patient with  
cardiovascular disease ..... Brewer Bryan (USA) **AL-13**

# Future Therapeutic Approaches for Atherosclerosis - Potential and Application of a Novel Statin -

Symposium sponsored by KOWA  
MSDA 2010, Marrakesh  
May 14, 2010 11:00-12:30  
La Salle des Ministres

Chair: *Toru Kita, Japan*

- **Opening remarks**  
*Toru Kita, Japan*
- **From the dawn of the statin era to the present day.**  
*Yoji Matsuzawa, Japan*
- **What are we looking for in a statin today and what are the future steps?**  
*Alberta Corsini, Italy*
- **Impact of nanotechnology-based selective delivery of pitavastatin for the development of innovative treatment of ischemic cardiovascular diseases.**  
*Kensuke Egashira, Japan*
- **Closing remarks**  
*Toru Kita, Japan*

Sponsored by



Saturday May 15<sup>th</sup>, 2010 / Morning

SALLE DES MINISTRES

09:00 am  
10:30 am

**ACADEMIC SESSION V**

**Metabolic and genetic biomarkers**

Chair: Carmena Rafael (Spain)

- The hidden faces of HLD and the non-LDL atherogenic factor ..... Davignon Jean (Canada) **AL-14**
- Biomarkers to predict type II diabetes - From single candidates to complex algorithms ..... Koenig Wolfgang (Germany) **AL-15**
- Recent genetic insights in the genetics of type II diabetes and the metabolic syndrome ..... Froguel Philippe (France) **AL-16**

10:30 am  
11:00 am

**Coffee Break**

11:00 am  
12:30 pm

**ACADEMIC SESSION VI**

**No traditional risk factors of cardiometabolic disease**

Chair: Sadikot Shaukat M. (India)

- Sleep, sleep apnea and metabolic syndrome ..... Ahmed Qanta (USA) **AL-17**
- Perivascular inflammation as a risk factor of cardiometabolic disease ..... Guzik Tomasz (Poland) **AL-18**
- Thioredoxin (Trx) and Thioredoxin-Interacting Protein (Txnip) are new actors in human disease: example of vascular diseases and type II diabetes ..... Rouis Mustapha (France) **AL-19**

## Saturday May 15<sup>th</sup>, 2010 / Afternoon

SALLE DES MINISTRES

12:30 pm ■ Lunch  
02:00 pm

02:00 pm ■ **ORAL COMMUNICATIONS SELECTED FROM ABSTRACTS**  
03:00 pm Chair: Rouis Mustapha (France)

• Conference 1

Associations between obesity, vitamin D deficiency and vitamin D receptor (VDR) polymorphisms in Caribbean type 2 diabetic subjects. .... Velayudom Fritz-Line (France) **P-30**

• Conference 2

Effect of apolipoprotein A5 haplotypes on plasma triglyceride is modified by total energy intake. The HAPIEE study. .... Hubacek Jaroslav A. (Czech Republic) **P-40**

• Conference 3

Fructose repress PPAR $\alpha$  independently of PP2A in FaO hepatoma cells ..... Alegret Maria (Spain) **P-27**

• Conference 4

Pseudocholinesterase as an additive marker of the risk of atherosclerosis and possible indicator of the degree of insulin resistance in metabolic syndrome ..... Muačević-Katanec Diana (Croatia) **P-39**

• Conference 5

Altered surface marker expression and function of circulating neutrophils in a fructose-induced rat model of metabolic syndrome ..... Tagzirt Madjid (France) **P-52**

03:00 pm ■ Coffee Break  
03:30 pm

03:30 pm ■ **POSTER SESSION**  
05:30 pm Chair: Fruchart Jean-Charles (France)

END OF THE CONGRESS

## List of poster abstracts

- P01 Parathyroid hormone levels in diabetic nephropathy: let's not forget metabolic syndrome**  
*Dr. Rengin Elsurur Afsar<sup>1</sup>, Dr. Baris Afsar<sup>1</sup>, Dr. Ertugrul Guner<sup>2</sup>, Dr. Idris Yildiz<sup>2</sup>*  
1 Zonguldak Ataturk State Hospital Department of Nephrology, Zonguldak, Turkey  
2 Zonguldak Ataturk State Hospital Department of Internal Medicine, Zonguldak, Turkey
- P02 Prevalence of metabolic syndrome among Qassim university personnel in Saudi Arabia**  
*Abdul Rahman Mohaimeed<sup>1</sup>, Issam E Barrimah<sup>1</sup>, Farid Midhet<sup>1</sup>, Hani A. Al-Shobaili<sup>2</sup>*  
1 Family & Community Medicine Dept., College of Medicine, Qassim University, Saudi Arabia  
2 Dermatology Dept., College of Medicine, Qassim University, Saudi Arabia
- P03 Overweight and obesity in reproductive women in North-Western Morocco**  
*Y. Aboussaleh, M. Farsi, M. El Hioui, A. Ahami*  
Ibn Tofail University – Kenitra - Morocco
- P04 Effect of vitamin D on zinc status and Carbohydrate metabolism and enzymes activities in Alloxan diabetic rats fed on zinc deficiency diet**  
*Zine Kechrid, Malika Hamdiken, Samira Bouhalit and Mohamed Khiari*  
Laboratory of Biochemistry and Microbiology, Department of Biochemistry, Faculty of Sciences, University of Annaba, Algeria.
- P05 Diabetes and metabolic syndrome during the menopausal transition of women in Serbia**  
*T. Beljic Zivkovic<sup>1</sup>, M. Andjelic Jelcic<sup>1</sup>, J. Vukcevic<sup>1</sup>, M. Vuksanovic<sup>1</sup>, B. Buric<sup>1</sup>, B. Jojic<sup>1</sup>, N. Milic<sup>2</sup>*  
1 Zvezdara University Medical Center, 2 Institut for Medical Statistics, Medical Faculty Belgrade, Serbia.
- P06 Plasma adiponectin and leptin levels and risk of myocardial infarction**  
*R. Jemaa<sup>1</sup>, A. Kallel<sup>1</sup>, Y. Sediri<sup>1</sup>, M.S. Mourali<sup>2</sup>, M. Feki<sup>1</sup>, R. Mechmeche<sup>2</sup>, and N. Kaabachi<sup>1</sup>*  
1 LR99ES11, Research Laboratory & Department of Biochemistry, Rabta University Hospital, Tunis, Tunisia.  
2 Department of Cardiology, Rabta University Hospital, Tunis, Tunisia.
- P07 Association of the metabolic syndrome with myocardial infarction in Tunisian male patients**  
*Jemaa R<sup>1</sup>, Sediri Y<sup>1</sup>, Kallel A<sup>1</sup>, Feki M<sup>1</sup>, Mourali M S<sup>2</sup>, Elasmı M<sup>1</sup>, Haj-Taieb S<sup>1</sup>, Omar S<sup>1</sup>, Sanhaji H<sup>1</sup>, Mechmeche R<sup>2</sup>, Kaabachi N<sup>1</sup>*  
1 Research Laboratory LR99ES11, Department of Biochemistry, Hospital Ia Rabta, Tunis, Tunisia  
2 Department of Cardiology, Hospital Ia Rabta, Tunis, Tunisia
- P08 Gender specific effect of pro12Ala polymorphism in peroxisome proliferator-activated receptor-2 gene on obesity risk and leptin levels in Tunisian population**  
*R. Jemaa<sup>1</sup>, S. Ben Ali<sup>1</sup>, Y. Sediri<sup>1</sup>, A. Kallel<sup>1</sup>, B. Ftouhi<sup>2</sup>, M. Feki<sup>1</sup>, M. Elasmı<sup>1</sup>, S. Haj-Taieb<sup>1</sup>, O. Souheil<sup>1</sup>, H. Sanhaji<sup>1</sup>, H. Slimene<sup>2</sup>, and N. Kaabachi<sup>1</sup>.*  
1 Research Laboratory LR99ES11, Biochemistry Department, Rabta University Hospital, Tunis, Tunisia.  
2 Endocrinology Department, Rabta University Hospital, Tunis, Tunisia.



**P09 Association of the Pro12Ala polymorphism in the PPAR $\gamma$ 2 gene with leptin level in obese type 2 diabetic patients**

Kallel A<sup>1</sup>, Sédiri Y<sup>1</sup>, Ftouhi B<sup>2</sup>, Feki M<sup>1</sup>, Elasmi M<sup>1</sup>, Haj Taieb S<sup>1</sup>, Sanhaji H<sup>1</sup>, Omar S<sup>1</sup>, Slimane H<sup>2</sup>, Jemaa R<sup>1</sup>, Kaabachi N<sup>1</sup>

1 Research Laboratory LR99ES11, Department of Biochemistry, Rabta University Hospital, Tunis, Tunisia.

2 Department of Endocrinology, Rabta University Hospital, Tunis, Tunisia.

**P10 The association of metabolic syndrome and food pattern in non-menopause women**

S. Haddad Tabrizi, M. Hajifaraj, F. Hossein Panah, A. Abadi, A. Houshiar Rad

International Branch of Shahid Beheshti University, Tehran, Iran

**P11 Additive value of ankle brachial index with TIMI risk scoring system for unstable angina/non-ST elevation myocardial infarction**

Pamela Rose L. Mancio M.D<sup>1</sup>, Dondi C. Lim M.D<sup>2</sup>, Alvin C. Lim M.D<sup>3</sup>

1 Principal Investigator, Resident, Department of Medicine, University of Santo Tomas Hospital, Philippines

2 Fellow, Section of Cardiology, University of Santo Tomas Hospital, Philippines

3 Consultant, Section of Cardiology, University of Santo Tomas Hospital, Philippines

**P12 The EPIMIL Cohort 5 years follow up: the clinical parameters precede the biological modifications of the metabolic syndrome**

C. Garcia<sup>1</sup>, H. Baizri<sup>1</sup>, O. Dupuy<sup>1</sup>, P. Burnat<sup>2</sup>, F. Ceppa<sup>2</sup>, L. Bordier<sup>1</sup>, H. Mayaudon<sup>1</sup>, B. Bauduceau<sup>1</sup> for the EPIMIL group.

Endocrinology<sup>1</sup> and Biology<sup>2</sup> departments, Begin hospital, Saint-Mandé, France

**P13 Hormonal regulation of the mouse adrenal melanocortinergic system**

Soltani Y<sup>1</sup>, Doghman M<sup>2</sup>, Gout J<sup>2</sup>, Rebuffet V<sup>2</sup>, Vigier M<sup>2</sup>, Hadj Bekkouche F<sup>1</sup>, Naville D<sup>2</sup>, Begeot M<sup>2</sup>

1 Laboratoire de biologie et physiologie des organismes, Faculté des sciences biologiques, USTHB, Algérie

2 Inserm, U855, Faculté de médecine Laënnec, Université Claude Bernard, Lyon, France.

**P14 Meeting the lipid lowering treatment targets in middle-aged patients admitted to the East-Tallinn Central Hospital (Estonia) for emergency PTCA**

E. Mäeots, MD, K. Traumann, RN BA Sc, K. Tutt, RN BA

East – Tallinn Central Hospital – Tallinn - Estonia

**P15 Carbon Monoxide prevents Ob-Rb transfected neuronal cells from ER stress-induced leptin resistance**

Min Zheng<sup>1</sup>, JiHwa Chung<sup>2</sup>, YeonSoo Joe<sup>2</sup>, Hyun-Ock Pae<sup>3</sup>, Hun-Taeg Chung<sup>2</sup>

1 Department of Medical Science of Biological Sciences, University of Ulsan

2 School of Biological Sciences, University of Ulsan

3 Department of Immunology, School of Medicine, Wonkwang University

**P16 Inhibition of ER stress-induced CRP expression by Carbon Monoxide**

Jihwa Chung<sup>1</sup>, Yeonsoo Joe<sup>1</sup>, Min Zheng<sup>1</sup>, Da-yong Shin<sup>1</sup>, Hyun-Ock Pae<sup>2</sup>, Hun-Taeg Chung<sup>1</sup>

1 School of Biological Sciences, University of Ulsan

2 Department of Immunology, School of Medicine, Wonkwang University

## List of poster abstracts

- P17** Awareness of diabetes mellitus among Saudi general population in Qassim Region, KSA.  
*Abdelmarouf H. Mohieldein, Mohammad A. Alzohairy, and Marghoob Hasan.*  
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Qassim, KSA.
- P18** Can we intervene? Reducing vascular stiffening as a consequence of cardiovascular event risks in primary care  
*E Akpınar<sup>1</sup>, I Bashan<sup>2</sup>*  
1 Cukurova University Medical Faculty Department of Family Medicine – Adana /Turkey  
2 Baskent University Medical Faculty Department of Family Medicine – Ankara /Turkey
- P19** The effect of statin and folic acid on high density lipoprotein, C-reactive protein and homocysteine levels: a role in the prevention of microangiopathy  
*Ljubic S, Mileta D, Vucic-Lovrencic M*  
Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Disease, Zagreb, Croatia
- P20** Prevalence of obesity and the overweight in Marrakesh  
*Errajraji. A<sup>1</sup>, El Ansari. N<sup>1</sup>, Essaadouni. L<sup>2</sup>*  
Department of Endocrinology and Metabolic Diseases, University Hospital Mohammed VI, Marrakesh  
Department of Internal Medicine, University Hospital Mohammed VI, Marrakesh
- P21** FFA, lipoproteins, LpAI particles and coronary risk factors in the type 2 diabetic  
*M. Harizi<sup>1</sup>, M. Hadj-habib<sup>2</sup>, N. Lemort<sup>3</sup>, B. Jacotot<sup>3</sup>*  
1- Central Laboratory of Biology, Sidi Bel Abbes, University Hospital (Algeria)  
2- Endocrino-diabetologia department of Sidi Bel Abbes, University Hospital  
3- ex. INSERM391 Unit. Henri Mondor Hospital Creteil (France)
- P22** Heart rate variability and ultrasound parameters in type 2 diabetes mellitus  
*L Poanta, M Porojan, DL Dumitrascu*  
University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca Romania
- P23** Diabetes mellitus, dislipidaemia and the anatomic characteristics of coronary disease in patients undergoing coronary revascularization surgery  
*Pupi L M, MD; Leonardi M, MD; Calabria F, MD; Sampó E, MD*  
Intensive Care Coronary Unit -Hospital de Clinicas "José de San Martín" - Buenos Aires- Argentina
- P24** Association of plasma phospholipids concentration with dietary saturated fatty acids intake in obesity  
*K. Charrad<sup>1</sup>, F. Ben Hassine<sup>3</sup>, Z. Aouni<sup>2</sup>, M. Hammami<sup>4</sup>, M. Sakly<sup>1</sup>, N. Attia<sup>1,4</sup>*  
1 Biochemistry (KC,NA) and Animal Physiology (MS) Laboratories, Faculty of Sciences, Bizerte, Tunisia  
2 Biochemistry Laboratory, Military hospital (HMPIT), Tunis, Tunisia  
3 Biochemistry Laboratory, CNSS, Bizerte, Tunisia  
4 Biochemistry Laboratory, Faculty of Medicine, Monastir, Tunisia

**P25 Lipid and vitamins A and E profiles in a group of hypothyroid patients**

*N. Ben Amara<sup>1</sup>, Z. Aouni<sup>1</sup>, N. Stambouli<sup>1</sup>, S. Kessraoui<sup>2</sup>, C. Mazigh<sup>1</sup>, N. Atia<sup>3</sup>, S. Machghoul<sup>1</sup>*

1 Biochemistry Laboratory, Military hospital (HMPIT), Tunis, Tunisia

2 Pharmacie Department

3 Biochemistry Laboratories, Faculty of Sciences, Bizerte, Tunisia

**P26 Effects of intermittent fasting in SAMP8 mice: the role of sirtuin 1**

*M. Pallàs<sup>1</sup>, M. Tajés<sup>1</sup>, J. Gutierrez-Cuesta<sup>1</sup>, D. Ortuño-Sahagun<sup>2</sup> and A. Camins<sup>1</sup>*

1 Unitat de Farmacologia i Farmacognòsia Facultat de Farmàcia, Institut de Biomedicina (IBUB), Centros de Investigació Biomèdica en Red de Enfermedades Neurodegenerativas (CIBERNED). Universitat de Barcelona. Nucli Universitari de Pedralbes. 08028 Barcelona, Spain.

2 Laboratorio de Desarrollo y Regeneración Neural, Instituto de Neurobiología. Departamento de Biología Celular y Molecular, CUCBA, Universidad de Guadalajara, Guadalajara, Jalisco, México

**P27 Fructose repress PPAR $\alpha$  independently of PP2A in FaO hepatoma cells**

*M. Alegret, A. Rebollo, A. Pedrosa, N. Roglans, J.C. Laguna*

Pharmacology Department, Faculty of Pharmacy and Biomedicine Institute (IBUB), University of Barcelona and Ciber Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.

**P28 Airflow obstruction and metabolic syndrome**

*Nada Bogdanović, Biljana Lazović*

University Clinical - Hospital center Dr Dragiša Mišović - Dedinje, Belgrade

**P29 Association between Adiponectin multimers, ADIPOQ T45G and coronary artery disease in Caribbean type 2 diabetic subjects.**

*L Foucan<sup>1</sup>, S Hedreville<sup>1,2</sup>, L Larifla<sup>1,2</sup>, S Maimaitiming<sup>3</sup>, J Deloumeaux<sup>1</sup>, N Ezourhi<sup>1</sup>, FL Velayoudom<sup>1,4</sup>, J Inamo<sup>1,5</sup>, A Atallah<sup>1,6</sup>, P Donnet<sup>1,4</sup>.*

1 Research Group, Clinical Epidemiology and Medicine, University of Antilles and Guyane, France.

2 Unit of Cardiology, University Hospital of Guadeloupe, France.

3 Inserm, U695 - Faculté de Médecine Xavier Bichat, Paris, France.

4 Unit of Diabetology, University Hospital of Guadeloupe, France.

5 Unit of Cardiology, University Hospital of Guadeloupe, France.

6 Unit of Cardiology, La Basse-Terre Hospital. Guadeloupe, France.

**P30 Associations between Obesity, Vitamin D Deficiency and Vitamin D receptor (VDR) polymorphisms in Caribbean type 2 diabetic subjects.**

*FL Velayoudom<sup>1,2</sup>, C Messerschmitt<sup>2</sup>, L Larifla<sup>1</sup>, S Maimaitiming<sup>3</sup>, S Benabdallah<sup>2</sup>, A Blanchet<sup>1</sup>, P Kangambega<sup>4</sup>, J Deloumeaux<sup>1</sup>, S Merle<sup>1</sup>, J.P Donnet<sup>1,2</sup>, C Massart<sup>5</sup>, F Bonnet<sup>6</sup>, L Foucan<sup>1</sup>.*

1 Research Group, Clinical Epidemiology and Medicine, University of Antilles and Guyane, France.

2 Unit of Endocrinology-Diabetology, University Hospital of Guadeloupe, France.

3 Inserm, U695 - Faculté de Médecine Xavier Bichat, Paris, France.

4 Unit of Diabetic foot, University Hospital of Guadeloupe, France.

5 Unit of Hormonology, University Hospital Pontchaillou of Rennes, France.

6 Unit of Endocrinology-Diabetology and nutrition, University Hospital Suf of Rennes, France.

## List of poster abstracts

- P31 Correlations between endothelial dysfunction and inflammatory biomarkers in patients with metabolic syndrome**  
*M. Popescu, C. Tanaseanu, I Tiglea, E. Moldoveanu, I. Chelaru, R. Saftoiu*  
University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
- P32 Vascular dysfunction in patients with systemic lupus erythematosus and metabolic syndrome**  
*C. Tanaseanu, St Tanaseanu, M. Popescu, A. Dumitrascu, I. Tiglea, E. Moldoveanu, M. Fronea*  
University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania
- P33 Achieving treatment goals using half-dose versus full-dose of ezetimibe/simvastatin (Vytorin)**  
*Yeun Tarl Fresner Ng Jao, MD, FASA, FESC, Ching-Chang Fang, MD, Yi Chen, MD, Ching-Lung Yu, MD, Shih-Pu Wang, MD.*  
Tainan Municipal Hospital, Tainan, Taiwan
- P34 Evidence of VKORC1 -1639 G>A polymorphism associated with type 2 diabetes mellitus**  
*A. Tavridou, I. Petridis, G. Ragia, V.G. Manolopoulos*  
Lab. of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece
- P35 Inflammation and dyslipidemia in Moroccan obese patients with or without metabolic syndrome**  
*Saile R.<sup>1</sup>, Essiarab F.<sup>1,2</sup>, Taki H.<sup>1</sup>, Kettani A.<sup>1</sup>, Ghalim N.<sup>2</sup>*  
1 Laboratory of Research on Lipoproteins and Atherosclerosis, Unit Associated with CNRST -URAC 34-, Hassan II University, Faculty of Sciences Ben M'sik, Casablanca, Morocco.  
2 Laboratory of Biochemistry, Research Department, Pasteur Institute of Morocco, Casablanca, Morocco.
- P36 Effect of individualized exercise training intervention on metabolic syndrome in obese children.**  
*O Ben Ounis, M Elloumi, M Zaouali, H ZouhaL, A Zbidi, Z Tabka.*  
Laboratoire des adaptations cardio-circulatoires, respiratoires, métaboliques et hormonales à l'exercice musculaire, faculté de médecine, Tunisie.  
Laboratoire Mouvement Sport Santé (M2S). UFR APS, Université Rennes 2, Campus la Harpe. 35044 Rennes, Cedex France.
- P37 Prevalence of onychomycosis and tinea pedis in diabetic population in our area**  
*<sup>1</sup>T. Exiara, <sup>2</sup>L. Papazoglou, <sup>1</sup>A. Konstantis, <sup>1</sup>A. Risggits, <sup>3</sup>M. Kouroupi, <sup>3</sup>E. Filippidou, <sup>1</sup>P. Poursanidis, <sup>1</sup>A. Kalpaka, <sup>1</sup>L. Mporgi, <sup>1</sup>S. Papanastasiou*  
<sup>1</sup>General Hospital of Komotini "Sismanogleio", Komotini, Greece, <sup>2</sup>Military Hospital of Alexandroupolis, Alexandroupolis, Greece, <sup>3</sup>Dimocritus University Hospital of Alexandroupolis, Alexandroupolis, Greece
- P38 Nonalcoholic fatty liver disease in patients with diabetes mellitus type 2**  
*<sup>1</sup>T. Exiara, <sup>2</sup>L. Papazoglou, <sup>1</sup>A. Konstantis, <sup>1</sup>A. Risggits, <sup>1</sup>P. Poursanidis, <sup>3</sup>M. Kouroupi, <sup>3</sup>E. Filippidou, <sup>1</sup>A. Kalpaka, <sup>1</sup>L. Mporgi, <sup>1</sup>S. Terzi, <sup>1</sup>S. Papanastasiou*  
<sup>1</sup>General Hospital of Komotini "Sismanogleio", Komotini, Greece, <sup>2</sup>Military Hospital of Alexandroupolis, Alexandroupolis, Greece, <sup>3</sup>Dimocritus University Hospital of Alexandroupolis, Alexandroupolis, Greece

**P39 Pseudocholinesterase as an additive marker of the risk of atherosclerosis and possible indicator of the degree of insulin resistance in metabolic syndrome**

*<sup>1</sup>D. Muačević-Katanec, <sup>2</sup>T. Poljičanin, <sup>3</sup>V. Bradamante, <sup>4</sup>D. Katanec, <sup>1</sup>Ž. Reiner*

1 Division of Metabolic Diseases, University Hospital Center, Zagreb, 2 Vuk Vrhovac University Clinic, Zagreb  
3 Dept. of pharmacology, School of Medicine, University of Zagreb, 4 School of Dental Medicine, University of Zagreb

**P40 Effect of apolipoprotein A5 haplotypes on plasma triglyceride is modified by total energy intake.**

**The HAPIEE study.**

*J.A. Hubacek PhD, A. Peasey, PhD, H. Pikhart PhD, M. Bobak, PhD*

**P41 Evaluating benchmarking to optimize management of type 2 diabetic patients: the Belgian data of the optimise study**

*M. P. Hermans <sup>1</sup>, E. Muls <sup>2</sup>, F. Nobels <sup>3</sup>, G. Krzentowski <sup>4</sup>, N. Claes <sup>5</sup>, N. Debacker <sup>6</sup>, A. Matthys <sup>7</sup>.*

1 UCL St-LUC, Brussels, Belgium; 2 UZ Gasthuisberg, Leuven, Belgium; 3 OLV Ziekenhuis, Aalst, Belgium; 4 CHU Charleroi, Charleroi, Belgium; 5 Universiteit Hasselt, Diepenbeek, Belgium; 6 Wetenschappelijk Instituut Volksgezondheid, Brussels, Belgium; 7 AstraZeneca, Brussels, Belgium

**P42 Streptozotocin and B cells damages on pancreas of a deserticol rodent (Gerbillus gerbillus)**

*A. Mallek <sup>1</sup>; N. Semiane <sup>1</sup>; A. Khalkhal <sup>1</sup>; F. Sekkal <sup>2</sup>; I. Oudjit <sup>3</sup>; K. Mokaddem <sup>4</sup>; Y. Dahmani <sup>1</sup>.*

1 LBPO/ Nutrition-métabolisme. FSB/USTHB, Alger, Algérie.  
2 Service de Diabétologie, CHU Mohamed Debaghine de Bab El Oued, Alger, Algérie  
3 Service de Diabétologie, CHU Ain Naadja, Alger, Algérie  
4 Service d'anatomie- pathologique, CHU Mustapha Bacha, Alger, Algérie

**P43 High blood pressure: a risk factor often associated with type 2 diabetes**

*F.Louda, A.Chadli, S.Elaziz, H.Elghomari, A.Farouqi*

Endocrinology, Diabetology, CHU IBN ROCHD-Casablanca-Morocco

**P44 Lipoprotein profile disturbances in Moroccan obese women with or without Metabolic Syndrome.**

*Essiarab F.<sup>1,2</sup>, Ghalim N.<sup>2</sup>, Saïle R.<sup>1</sup>*

1 Laboratory of Research on Lipoproteins and Atherosclerosis, Unit associated with CNRST - URAC 34-, Hassan II University, Faculty of Sciences Ben M'sik, Casablanca, Morocco.  
2 Laboratory of Biochemistry, Research Department, Pasteur Institute of Morocco, Casablanca, Morocco.

**P45 Relationships between hyperuricemia and components of metabolic syndrome in Tunisian obese adults**

*Khelifi N., Mnif S., Jamoussi H., Hammami F., Amrouch Ch., Boussama D., Blouza S.*

Obesity research unit, National Institute of Nutrition – Tunis, Tunisia.

**P46 Congenital generalized lipodystrophy: a case report**

*F.Ouhdouch, N. El Ansari*

Department of Endocrinology and Metabolic Diseases, Mohammed VI university hospital of Marrakech

## List of poster abstracts

**P47 The atrial natriuretic peptide gene and cardiometabolic risk factors in a Caribbean population**

*L Larifla<sup>1,2</sup>, S Maimaitiming<sup>3</sup>, FL Velayoudom<sup>1,4</sup>, A Blanchet<sup>1,2</sup>, S Hedreville<sup>2</sup>, J Bangou<sup>1</sup>*

*R Billy-Brissac<sup>2</sup>, M Hedreville-Montout<sup>2</sup>, F Roques<sup>1</sup>, JP Donnet<sup>1,4</sup>, R Roussel<sup>3</sup>, L Foucan<sup>1</sup>.*

1 Research Group, Clinical Epidemiology and Medicine, University of Antilles and Guyane, France.

2 Unit of Cardiology, University Hospital of Guadeloupe, France.

3 Inserm, U695 - Xavier Bichat Faculty of Medicine, Paris, France.

4 Unit of Endocrinology-Diabetology, University Hospital of Guadeloupe, France.

**P48 Contribution of the 6 minutes walk test in the exploration of the incapacity of the type 2 diabetes mellitus patients**

*Latiri I<sup>1</sup>, Ben Saad H<sup>1</sup>, El Bey R<sup>1</sup>, Charfeddine B<sup>2</sup>, Maarouf R<sup>3</sup>, Tabka Z<sup>1</sup>, Zbidi A<sup>1</sup>*

1. Laboratoire de Physiologie et des Explorations Fonctionnelles – Faculté de Médecine de Sousse.

2. Laboratoire de Biochimie du Groupement de Santé de Base de la Ville de Sousse

3. Groupement de Santé de Base de la ville de Sousse.

**P49 Lipid profile after weight management**

*Amrouche–Rached C., Gammoudi A., Mahjoub F., Jamoussi H., Tarchoune D., Blouza-Chabchoub S.*

Service A de diabétologie Nutrition et maladies métaboliques, Institut National de Nutrition de Tunis, Tunisie.

**P50 LDL-C: “lower is better”; but what about HDL-C ?**

*Amrouche–Rached C., Falfoul E., Gaigi I., Khelifi N., Mnif S., Sellami H. Jamoussi H., Tarchoune D., Blouza-Chabchoub S.*

Service A de diabétologie Nutrition et maladies métaboliques, Institut National de Nutrition de Tunis, Tunisie.

**P51 Targets of statin therapy: LDL cholesterol, non HDL cholesterol in type 2 diabetes**

*Berriche. O, Amrouche. C, Jamoussi. H, Blouza–Chabchoub. S.*

Department of Diabetology and metabolic diseases -Nutritional Institut of Nutrition, Tunisia

**P52 Altered surface marker expression and function of circulating neutrophils in a fructose-induced rat model of metabolic syndrome**

*M. Tagzirt (Dr), J. Breyne, D. Corseaux, S. Susen, A. Ung, V. Grard, M. Barthelemy, F. Mouquet, B. Jude, A. Dupont*

Univ Lille Nord de France, UDSL, IFR 114, EA 2693, Faculté de Médecine, Lille, France

**P53 Adiponectin and insulin resistance of peripheral tissues**

*Gkini M.-A.<sup>1</sup>, Panagiotopoulos N.<sup>2</sup>*

<sup>1</sup> Medical School of Aristotle University of Thessaloniki , Greece , <sup>2</sup> 401 General Army Hospital , Athens , Greece

**P54 Comparison of metabolic control and metabolic risk factors in type 2 diabetic patients with and without diabetic retinopathy**

*S. Radenković, M. Pešić, R. Kocić, D. Dimić, M. Velojić Golubović, D. Stojić, S. Kostić, D. Radojković, V. Ćirić*

Clinic for Endocrinology, Diabetes and Diseases of Metabolism; Clinical Center Nis; Niš, Serbia

**P55 Non high density lipoprotein cholesterol in type 2 diabetes mellitus with hypertension**

*Berriche. O, Jamoussi. H, Amrouche. C, Blouza-Chabchoub. S.*

Department of Diabetology and metabolic diseases -Nutritional Institut of Nutrition, Tunisia

**P56 Biological investigations of anti-oxidant, antimicrobial and antihemolysis properties of *Thymus satureioides* collected in Tafilalet region, south-east of Morocco**

*Mhamed Ramchoun<sup>1,4</sup>, Khalid Sellam<sup>2</sup>, Hicham Harnafi<sup>3</sup>, Chakib Alem<sup>4</sup>, Mohamed Benlyas<sup>4</sup>, Lhoussain Elghaffari<sup>2</sup>, Souliman Amrani<sup>1</sup>*

1 Laboratory of Biochemistry, Department of Biology, Faculty of Sciences, 60 000 Oujda, Morocco.

2 Department of Biology, Faculty of Sciences & Techniques 52000 Errachidia, Morocco.

3 Department of Life Sciences, Faculty of Sciences & Techniques 23000 Beni Mellal, Morocco.

4 Department of Biology, Faculty of Sciences & Techniques 52000 Errachidia, Morocco.

**P57 Association between apolipoprotein E gene polymorphism and atherogenic lipoprotein profile in a long term hemodialysis patients**

*H. Taki<sup>1</sup>, H. Lahrach<sup>1</sup>, F. Essiarab, A Kettani<sup>1</sup>, N Ghalim<sup>2</sup>, B. Ramdani<sup>3</sup> R. Saïle<sup>1</sup>*

1 Laboratory of Research on Lipoproteins and Atherosclerosis, Unit Associated with CNRST -URAC 34-, Hassan II University, Faculty of Sciences Ben M'sik, Casablanca, Morocco.

2 Laboratory of Biochemistry, Pasteur Institute of Morocco, Casablanca;

3 Nephrology and Haemodialysis Department, Ibn Rochd Hospital, Casablanca, Morocco.

**P58 Cardiometabolic risk in children and adolescents exposed to maternal diabetes mellitus in utero**

*Jamoussi H., Mnif S., Khelifi N., Sallemi H., Amrouch Ch., Boussama D., Blouza S.*

Obesity research unit, National Institute of Nutrition – Tunis, Tunisia.

**P59 Antioxidant, acute along with chronic hypolipemic effects of the polyphenolic fraction from *Thymus atlanticus* in hyperlipidemia mice models**

*Mhamed Ramchoun<sup>1,3</sup>, Hicham Harnafi<sup>2</sup>, Chakib Alem<sup>3</sup>, Mohamed Benlyas<sup>3</sup>, Souliman Amrani<sup>1</sup>*

1 Department of Biology, Faculty of Sciences, University Mohammed I, 60 000 Oujda, Morocco.

2 Department of Life Sciences, Faculty of Sciences & Techniques, 23000 Beni Mellal, Morocco.

3 Department of Biology, Faculty of Sciences & Techniques, University My Ismail, 52000 Errachidia, Morocco.

## Information to the faculty and poster authors

### YOU ARE A CHAIRPERSON

We thank you for proceeding to the CONFERENCE ROOM (Salle des Ministres) at least 15 minutes prior to the beginning of the session you are chairing.

Speakers have to comply with the speaking time which has been allotted to them.

We thank you in advance for seeing to this parameter.

### YOU ARE A SPEAKER

We thank you for proceeding to the PREVIEW ROOM (Reda 3) at least 30 minutes prior to the beginning of the session in which you will give a lecture.

Thank you for conforming to the instructions given by the chairpersons of your session.

### PREVIEWING YOUR ORAL PRESENTATION

In order to insure the easy running of the scientific sessions, we recommend each speaker to run a few checks on his oral presentation (PowerPoint) or make some technical trials enough time in advance in the PREVIEW ROOM (Reda 3) located level – 1.

A computer expert will welcome you in the PREVIEW ROOM according to the following schedule:

**Wednesday May 12<sup>th</sup>** 4.00 p.m. - 6.00 p.m.      **Friday May 14<sup>th</sup>** 7.30 a.m. - 6.00 p.m.

**Thursday May 13<sup>th</sup>** 7.30 a.m. - 6.00 p.m.      **Saturday May 15<sup>th</sup>** 8.00 a.m. - 5.00 p.m.

(closing between 12.30 p.m. and 01.30 p.m. for lunch)

### YOU ARE A POSTER AUTHOR

Posters will be displayed for the whole length of the congress in the Espace Ménara located on the level 0 close to the congress welcome desk area.

Fixing materials will be available at the congress welcome desk.

Poster authors are kindly requested to comply with the following schedule for mounting and removing their posters:

**MOUNTING** as from 4.00 p.m. on Wednesday May 12<sup>th</sup>

**REMOVAL** as from 11.00 a.m. on Sunday May 16<sup>th</sup>

A poster session will take place on Saturday May 15<sup>th</sup>, 2010 from 3.30 p.m. to 5.30 p.m.

We thank you for standing close to your poster during coffee breaks in order to discuss your work with delegates. Here is the schedule of the different coffee breaks :

**Thursday May 13<sup>th</sup>** 10.45 a.m. - 11.15 a.m.      and      3.30 p.m. - 4.00 p.m.

**Friday May 14<sup>th</sup>** 10.30 a.m. - 11.00 a.m.      and      3.30 p.m. - 4.00 p.m.

**Saturday May 15<sup>th</sup>** 10.30 a.m. - 11.00 a.m.      and      3.00 p.m. - 3.30 p.m.

### ABSTRACT CODIFICATION (ORAL AND POSTER COMMUNICATIONS)


Abstracts related to the oral communications begin either with « AL » or with « LL »

“AL” stands for Academic Lecture (i.e. a lecture given within an Academic Session) and “LL” stands for Laboratory Lecture (i.e. a lecture given within a Laboratory Symposium i.e. a Sponsored Symposium)

The last two digits correspond to the abstract number.

Abstracts related to the poster communications begin with a « P » + abstract number.





**MSDA**

**2011**

**8<sup>th</sup>** Metabolic Syndrome, type II Diabetes  
and Atherosclerosis congress

**MARRAKESH**  
**JUNE**  
1<sup>st</sup> - 5<sup>th</sup> 2011

**ORGANIZING / SCIENTIFIC COMMITTEE**

Chair: Pr Jean-Charles FRUCHART

**ORGANIZING SECRETARIAT**

PLB. Organisation Inc. / MSDA 2011

Phone: +33 (0)1 39 04 24 24 - Fax: +33 (0)1 39 04 07 41 - Email: msda2011@agence-plb.com

Web site: [www.msdacongress.com](http://www.msdacongress.com)

## General information

### DATES AND CONGRESS VENUE

The congress will take place in Marrakech (Morocco) From Wednesday May 12<sup>th</sup> through Saturday May 15<sup>th</sup>, 2010.

#### Palais des Congrès de Marrakech / Marrakech Congress Center

Boulevard Mohamed VI - 40000 Marrakech (Morocco)

Phone: +212(0) 524 33 91 00 - Fax: +212(0) 524 33 91 20/21

**Web site:** [www.mansoureddahbi.com](http://www.mansoureddahbi.com)

### SCIENTIFIC AND ORGANIZING COMMITTEE

**Chair:** Pr Jean-Charles FRUCHART

President of the International Atherosclerosis Society

**Members:** Dr Jamila FRUCHART-NAJIB, Pr Patrick DURIEZ, Pr Michel HERMANS

### ORGANIZING SECRETARIAT

#### PLB Organisation Inc. / MSDA 2010

Hôtel de Créquy - 15 rue de Pontoise - 78100 Saint-Germain-en-Laye (France)

Phone: (+33) (0)1 39 04 24 24 - Fax: (+33) (0)1 39 04 07 41

Email: [msda2010@agence-plb.com](mailto:msda2010@agence-plb.com)

**Managing Director:** Mr Pascal LE BORGNE

**Congress manager:** Mrs Lily-Claude LEVASSEUR

### OFFICIAL LANGUAGE

The official language of the congress will be English.

Simultaneous translation from English to French will be provided.

### REGISTRATION

REGISTRATION FEES			
DEADLINES STATUS	Before 31/12/2009	From 01/01/2010 to 31/03/2010	From 01/04/2010 and on site registration
PHYSICIAN	500 €	540 €	600 €
ABSTRACT AUTHOR	239 €	239 €	239 €
STUDENT*	239 €	270 €	300 €

\*Please enclose the official statement or copy of license (valid ID required)

#### The registration fee includes the:

- attendance to all scientific sessions
- access to the exhibit and poster areas
- attendance certificate
- badge and congress bag
- final program and abstract book
- lunches on 13, 14 and 15 May
- coffee breaks on 13, 14 and 15 May

### HOTELS

Please contact the organizing secretariat for any accommodation arrangements.

### MSDA 2010 ONLINE SERVICES

[www.msdacongress.com](http://www.msdacongress.com)

(registration, accommodation and abstract forms will be available on the website)

Please refer to the website for any further information you may require regarding your participation to the congress.

### OFFICIAL CARRIER



Event: MSDA 2010

Event ID: **07979AF**

Valid for travel from 07/05/2010 to 21/05/2010

Event location: Marrakech, Maroc

Discounts are applied to a wide range of airfares on all Air France and KLM flights worldwide, if passengers are travelling on the following classes of travel: Espace Affaires [Business] and Economique [Coach].

**To access the preferential fares granted for this event, use this link:**

**[www.airfranceklm-globalmeetings.com](http://www.airfranceklm-globalmeetings.com)**

**or the website of the event: [www.msdacongress.com](http://www.msdacongress.com)**

This present document of the event serves to justify the application of the preferential airfare. Keep it with you as you may be asked for it at any point of your journey.

To locate your nearest Air France sales point, consult: [www.airfrance.com](http://www.airfrance.com)

## Congress from A to Z

### ABSTRACT BOOK

This book is available to all registered delegates.

Abstracts have been coded according to the type of lecture (see the "Lectures" section).

- **AL** (Academic Lectures - Academic Session)
- **LL** (Laboratory Lectures - Sponsored Symposia and Lunch Debates)

### BADGES

All participants are kindly requested to wear badge at all times throughout the congress and during social events.

**BLUE** for DELEGATES

**GREEN** for EXHIBITORS

**RED** for FACULTY (speakers and chairpersons)

**YELLOW** for ORGANIZATION

### CERTIFICATE OF ATTENDANCE

Each registered participant will find the corresponding certificate of attendance in the congress kit at the congress welcome desk.

### COFFEE BREAKS – SALLE ROYALE - LEVEL 0

They will be served to all registered participants during the following time schedule:

Thursday May 13<sup>th</sup> from 10.45 a.m. to 11.15 a.m. and from 03.30 p.m. to 04.00 p.m.

Friday May 14<sup>th</sup> from 10.30 a.m. to 11.00 a.m. and from 03.30 p.m. to 04.00 p.m.

Saturday May 15<sup>th</sup> from 10.30 a.m. to 11.00 a.m. and from 03.00 p.m. to 03.30 p.m.

### EXHIBITION – SALLE ROYALE - LEVEL 0

Opening hours of the exhibition:

**Wednesday May 12<sup>th</sup>** 5.00 p.m. - 6.30 p.m.

**Thursday May 13<sup>th</sup>** 8.00 a.m. - 6.00 p.m.

**Friday May 14<sup>th</sup>** 8.00 a.m. - 6.00 p.m.

**Saturday May 15<sup>th</sup>** 8.30 a.m. - 5.30 p.m.

### INSURANCE

The organizers cannot be held liable for medical, travel or personal claims. Participants are strongly advised to seek personal insurance coverage.

### LECTURES

Please note that lectures have been coded as follows:

- **AL** (Academic Lectures - Academic symposia)
- **LL** (Laboratory Lectures - Supported symposia and lunch debates)

### LUNCHES – SALLE ROYALE - LEVEL 0

They will be served to all registered participants during the following time schedule:

Thursday May 13<sup>th</sup> 12.45 p.m. - 02.00 p.m.

Friday May 14<sup>th</sup> 12.30 p.m. - 02.00 p.m.

Saturday May 15<sup>th</sup> 12.30 p.m. - 02.00 p.m.

**NO SMOKING**

Please remember that smoking is prohibited within the Salle des Ministres and in the poster and exhibition areas.

**OPENING CEREMONY – SALLE DES MINISTRES - LEVEL -1**

All registered delegates are invited to attend the Congress Opening Ceremony to be held on Wednesday, May 12<sup>th</sup>, 2010 from 5.30 p.m. to 6.30 p.m.

**POSTER DISPLAY – SALLE ROYALE - LEVEL 0**

Posters are displayed for the whole duration of the congress. They must be set up in the poster display located level 0 (Espace Ménara). Please set up your poster according to the poster number you have been given (refer to the list in the poster display area). Hanging fixtures are available in this area. Authors are requested to mount their poster as of 4.00 p.m. on Wednesday May 12<sup>th</sup>, 2010.

**OPENING HOURS OF THE POSTER EXHIBITION**

<b>Wednesday May 12<sup>th</sup></b>	4.00 p.m. - 6.30 p.m.
<b>Thursday May 13<sup>th</sup></b>	8.00 a.m. - 6.00 p.m.
<b>Friday May 14<sup>th</sup></b>	8.00 a.m. - 6.00 p.m.
<b>Saturday May 15<sup>th</sup></b>	8.30 a.m. - 5.30 p.m.
<b>Sunday May 16<sup>th</sup></b>	8.30 a.m. - 11.00 a.m.

**PREVIEW ROOM – REDA 3 - LEVEL -1**

In order to insure the easy running of the congress, all speakers must proceed to the Preview room / Slide center in advance in order to have their oral presentation loaded. A computer technician will be in the Preview room / Slide center (Reda 3, level -1) according to the following schedule:

<b>Wednesday May 12<sup>th</sup></b>	4.00 p.m. - 6.00 p.m.
<b>Thursday May 13<sup>th</sup></b>	7.30 a.m. - 6.00 p.m.
<b>Friday May 14<sup>th</sup></b>	7.30 a.m. - 6.00 p.m.
<b>Saturday May 15<sup>th</sup></b>	8.00 a.m. - 5.00 p.m.

(closing between 12.30 p.m. and 01.30 p.m. – lunch time)



CONTINUING PROFESSIONAL DEVELOPMENT (CPD) SERIES:

# “DIABETES ASIA 2010” CONFERENCE

October 6 – 10, 2010. Kuching, Sarawak, MALAYSIA



## An Invitation

The 9<sup>th</sup> CPD Diabetes Asia Conference 2010 “DAC 2010” will highlight recent advances in diabetes care especially relevant to Asia with the rapidly increasing prevalence of diabetes.

A number of diabetes societies/associations are invited to be co-organisers of “DAC 2010” to make it more relevant and interactive.

Additionally, delegates will, for the first time, have the opportunity to experience Sarawak’s diverse culture and appreciate its unique flora and fauna.

**Please register early to enjoy “Early Bird” discount registration. Special rates for hotel accommodation and airfares are also available with early registration.**

### \*\*Scientific Programme:

Diabetes Asia Conference 2010 (“DAC 2010”) will cover subjects which will be of interest to healthcare professionals responsible for the care of people with diabetes. The focus of the Conference is on advances in diabetology and related fields, delivered through plenary lectures, symposiums, free papers and meet-the-experts sessions.

Emphasis is on the practical management of adult and childhood diabetes, micro- and macrovascular complications and related conditions such as cardiovascular diseases and lipid abnormalities. Special sessions will cover psychosocial aspects of the disease, the diabetes ‘epidemic’ and public health issues in the prevention and control of diabetes.

As previously, the “Young Investigator Award” will also be organised.

### \*\*Conference Faculty:

Distinguished international experts in diabetology from Europe, the USA, Australia, New Zealand, Middle East, China, Japan, Korea and other Asian countries will be invited to complement local specialists for the Faculty.

### \*\*Registration Fees:

Registration	Early Bird Before 31st July 2010		After 31st July 2010	
	Local	Foreign	Local	Foreign
Delegate	RM850	USD650	RM950	USD750
Allied Health/ Students*	RM800	USD600	RM900	USD700

\* Official endorsement from institution is required.



**Conference Venue:** Borneo Convention Centre Kuching, Sarawak, MALAYSIA

Organised by:



Endorsed by:



Supported by:



For enquiries, please contact the National Diabetes Institute.

\*\* Subject to change

Official media partner:



# The Unfinished Business in Vascular Risk Reduction

Solvay Pharmaceuticals  
MSDA 2010, Marrakesch  
Satellite Symposium

May 13, 2010 • 11:15-12:45  
La Salle des Ministres

Chair: Jean-Charles Fruchart, France

- Defining and addressing the Residual Vascular Risk;  
The atherogenic dyslipidemia factor  
Jean-Charles Fruchart, France
- How ACCORD will impact the way  
we treat patients with T2D?  
Marshall Elam, USA
- FIELD: Anything new?  
Richard O'Brien, Australia
- Fibrates & Statins: Combination therapy,  
the way forward  
Thomas Bersot, USA